clinical trial · NCT06000501
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
NYU Langone Health·phase4·completed·n = 29
Adult Attention Deficit Hyperactivity DisorderSerdexmethylphenidate/dexmethylphenidate
brief summary
This is a single-site study. One purpose of this trial is to extend the safety and efficacy evidence basis for Azstarys in adults with ADHD. This open-label, treatment study will examine the efficacy of Azstarys on ADHD symptoms using the AISRS 18-item total score on the AISRS-expanded; the Adult ADHD Investigator Symptom Rating Scale. The investigators will also examine Executive Function later in the day (early evening, about 12 hours after first morning dosing).
started
Nov 13, 2023
primary completion
Jul 3, 2024
completion
Jul 17, 2024
last updated
Jul 29, 2025
official title
An Open-Label Treatment, Investigator-Initiated Study, on the Duration and Efficacy of Azstarys (Serdexmethylphenidate and Dexmethylphenidate) on Adult ADHD Symptoms and Executive Function in Early Evening
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol